Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Deadline for written submissions extended to 12:00 on Wednesday 15 November 2017
2017-11-08

Deadline for written submissions extended:  Investigation/review into the handling of student protests on the Bloemfontein and Qwaqwa campuses by private security companies during october 2017.

A panel, consisting of Mr Ashraf Mahomed and Ms Nomfundo Walaza, has been appointed by the University of the Free State (UFS) to investigate/review the handling of student protests on the Bloemfontein and Qwaqwa Campuses by private security companies during October 2017. 

Mr Ashraf Mahomed is an attorney and director at Ashraf Mahomed Attorneys in Cape Town. He specialises in constitutional law, administrative law, public law, alternative dispute resolution (including mediation, arbitration, negotiation and facilitation), and land reform law. Mr Mahomed serves as a board member of the Dullah Omar Institute (DOI) for Constitutional Law, Governance and Human Rights at the University of the Western Cape, as well as the Tshisimani Centre for Activist Education. He recently completed his second term as President of the Cape Law Society (CLS).
 
Ms Nomfundo Walaza is a clinical psychologist who has worked in the human rights field for the past two decades. For the past nine years, she has served as the CEO of the Desmond Tutu Peace Centre and also served for 11 years as the Executive Director of the Trauma Centre for Survivors of Violence and Torture in Cape Town. Ms Walaza is currently the Executive Director of PeaceSystems – a civil-society organisation that supports the development of sustainable institutions and systems that prevent, manage, and resolve conflict in African societies.
 
This is an independent panel, which was requested by the Rector and Vice-Chancellor of the UFS on behalf of the UFS Executive, and supported by the President of the Central Student Representative Council on behalf of the student body. 

Submissions by students and staff are awaited and can be submitted as follows:
 
1.       Written submissions
 
The deadline for written submissions has been extended to 12:00 on Wednesday 15 November 2017. Submissions can be sent to news@ufs.ac.za.
 
2.       Oral submissions

The panel will visit the campuses as follows to receive oral submissions:

Bloemfontein Campus:
Monday 13 November 2017
Time: 09:00-17:00 
Venue: SRC Chambers, Steve Biko Building

Kindly confirm attendance of the sessions by contacting Ms Rochelle Ferreira at +27 51 401 9808 or FerreiraR1@ufs.ac.za by 14:00 on Friday 10 November 2017.

Qwaqwa Campus:
Tuesday 14 November 2017
Time: 09:00-17:00 
Venue: Senate Hall, Intsika Building

Kindly confirm attendance of the sessions by contacting Ms Thabile Zuma at +27 58 718 5094 or ZumaMT@ufs.ac.za by 14:00 on Friday 2017. 

Enquiries can be directed to Mr JC van der Merwe at vdmjc@ufs.ac.za

 

Released by:
Lacea Loader (Director: Communication and Brand Management)
Telephone: +27 51 401 2584 | +27 83 645 2454
Email: news@ufs.ac.za | loaderl@ufs.ac.za
Fax: +27 51 444 6393

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept